Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Köhler

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Frontiers in Medicine|March 1, 2017
Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting ParadigmsJens Köhler
Theoretical Biology & Medical Modelling|September 11, 2007
The allosteric modulation of lipases and its possible biological relevanceJens Köhler, Bernhard Wünsch
Future Oncology (London, England)|April 24, 2014
LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancerJens Köhler, Martin Schuler
Onkologie|September 21, 2013
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a reviewJens Köhler, Martin Schuler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2021
Amivantamab: Treating <i>EGFR</i> Exon 20-Mutant Cancers With Bispecific Antibody-Mediated Receptor DegradationJens Köhler, Pasi A Jänne
International Journal of Molecular Sciences|April 3, 2021
If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for <i>KRAS</i>-Mutant Lung CancerJens Köhler, Pasi A Jänne
European Journal of Medicinal Chemistry|March 30, 2011
Synthesis of 4-(aminoalkyl) substituted 1,3-dioxanes as potent NMDA and σ receptor antagonistsTina Utech, Jens Köhler, Bernhard Wünsch
Transactions of the Royal Society of Tropical Medicine and Hygiene|January 6, 2009
Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycleKatrin Breitbach, Jens Köhler, Ivo Steinmetz
Chemical Communications (Cambridge, England)|June 14, 2011
Post-polymerization functionalization of linear polyglycidol with diethyl vinylphosphonateJens Köhler, Helmut Keul, Martin Möller
JAMA|December 16, 2010
Cholecystectomy in a trial of adjuvant chemotherapy after pancreatic cancer resectionAttila Dubecz, Jens Köhler, Hubert J Stein
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Frontiers in Medicine|March 1, 2017
Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting ParadigmsJens Köhler
Theoretical Biology & Medical Modelling|September 11, 2007
The allosteric modulation of lipases and its possible biological relevanceJens Köhler, Bernhard Wünsch
Future Oncology (London, England)|April 24, 2014
LUX-Lung 3: redundancy, toxicity or a major step forward? Afatinib as front-line therapy for patients with metastatic EGFR-mutated lung cancerJens Köhler, Martin Schuler
Onkologie|September 21, 2013
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a reviewJens Köhler, Martin Schuler
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2021
Amivantamab: Treating <i>EGFR</i> Exon 20-Mutant Cancers With Bispecific Antibody-Mediated Receptor DegradationJens Köhler, Pasi A Jänne
International Journal of Molecular Sciences|April 3, 2021
If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for <i>KRAS</i>-Mutant Lung CancerJens Köhler, Pasi A Jänne
European Journal of Medicinal Chemistry|March 30, 2011
Synthesis of 4-(aminoalkyl) substituted 1,3-dioxanes as potent NMDA and σ receptor antagonistsTina Utech, Jens Köhler, Bernhard Wünsch
Transactions of the Royal Society of Tropical Medicine and Hygiene|January 6, 2009
Induction of protective immunity against Burkholderia pseudomallei using attenuated mutants with defects in the intracellular life cycleKatrin Breitbach, Jens Köhler, Ivo Steinmetz
Chemical Communications (Cambridge, England)|June 14, 2011
Post-polymerization functionalization of linear polyglycidol with diethyl vinylphosphonateJens Köhler, Helmut Keul, Martin Möller
JAMA|December 16, 2010
Cholecystectomy in a trial of adjuvant chemotherapy after pancreatic cancer resectionAttila Dubecz, Jens Köhler, Hubert J Stein
Pageof 8